VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedside.

Oncotarget · 2016 · PMC5008282 · PMID 26789111

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The randomized phase 3 ZEAL trial trial showed a positive trend in PFS, but no significant increase, when vandetanib was combined with chemotherapy in second-line treatment [ 32 ].

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.